source
- Personalized mRNA vaccine cuts melanoma recurrence risk by 42% in trialA recent study of a personalized mRNA cancer vaccine showed a 42% reduction in disease recurrence for patients with melanoma compared with the standard of care. The vaccine is tailored to each pat…
- Pathos AI secures $237M Series E funding at $3B valuation, partners with Bristol Myers on neurosciencePathos AI, an AI-focused biotech based in New York, announced it has closed a Series E financing round raising $237 million. The round values the company at $3 billion, reflecting investor confide…